

SIVUH Pharmacy Department Document. Version 2. Updated by F. O'Regan. Approved by SIVUH Medication Safety Committee 08/2024, Drug & Therapeutics Committee 09/2024

# Guidance on the management of acute hypomagnesaemia in adults

For the purpose of this document, the normal reference range used for serum magnesium is 0.7-1.0 mmol/L.


### Signs and symptoms of low magnesium:

- Nausea, vomiting
- Lethargy, muscle weakness, drowsiness
- Tetany, tremor, twitching, agitation
- Vertigo
- Confusion
- Cardiac arrhythmias
- Seizures
- Hypomagnesaemia may cause secondary hypocalcaemia and hypokalaemia

#### Causes of low magnesium:

- Reduced intake e.g. anorexia, malabsorption due to short bowel, coeliac disease, Crohn's disease
- Excessive losses e.g. in diarrhoea, stoma or fistula output, NG losses, renal losses
- Chronic alcoholism
- Uncontrolled diabetes
- Ketoacidosis
- Disorders of the parathyroid gland
- Low vitamin D levels
- Acute pancreatitis
- Re-feeding syndrome
- Severe burns
- Drugs e.g. aminoglycosides, amphotericin B, ciclosporin, cisplatin, theophylline, proton pump inhibitors, digoxin and diuretics.

## Oral treatment of low magnesium



- Oral magnesium replacement should be considered first, as a sudden rise in serum magnesium concentration (as seen following intravenous replacement) partially removes the stimulus for magnesium retention, and up to 50% of the infused magnesium is excreted in the urine.
- Oral magnesium salts commonly cause diarrhoea (reduced by administration with/ after food).




SIVUH Pharmacy Department Document. Version 2. Updated by F. O'Regan.



## Approved by SIVUH Medication Safety Committee 08/2024, Drug & Therapeutics Committee 09/2024

## IV treatment of low magnesium

- Product available for IV administration is Magnesium Sulfate 50% w/v concentrate (1g/2mL).
- Each 1g contains 4 mmol Mg<sup>+2</sup>.
  - The 50% solution MUST be further diluted before use mix very thoroughly to avoid layering.
    - Refer to SIVUH IV administration guideline for magnesium.
      - Max concentration for peripheral administration = 5% (50mg/ml). Can use 10% (100mg/ml) if fluid restrictedmonitor for phlebitis.
- Patients with severe signs and symptoms of hypomagnesemia should receive IV magnesium with continuous cardiac monitoring. Continuous cardiac monitoring includes ECG, heart rate, blood pressure and respiratory rate monitoring.



- Up to 50% of an IV dose may be eliminated in the urine, therefore, slower administration may improve retention.
- If patient is symptomatic, a maximum administration rate of 2g per hour can be used.
- A maximum total dose of 40g of magnesium sulfate (160mmol of Mg<sup>+2</sup>) may be required over a 5 day period to replace the deficit (allowing for urinary losses).
- After initial intravenous administration, it may be appropriate to give oral magnesium supplements to replenish the magnesium stores.
- In emergency situations, a maximum rate of 9g per hour can be used.
- Magnesium is renally cleared. Magnesium (especially via the intravenous route) should be used with caution in patients with renal impairment.

## References

- 1. SIVUH IV guidelines monograph for magnesium, 2023
- 2. Galway University Hospital IV guidelines monograph for magnesium, 2019
- 3. Guideline for the Management of Hypomagnesaemia in Adults, Gloucester Hospitals NHS Foundation Trust, October 2021
- 4. Hypomagnesaemia a guide for GPs, Royal United Hospitals Bath NHS Foundation Trust, January 2021
- 5. How is acute hypomagnesaemia treated in adults?, UK Medicines Information, November 2020
- 6. Hypomagnesemia: Evaluation and treatment, UpToDate, October 2022, https://www.uptodate.com/contents/hypomagnesemia-evaluation-and-treatment






SIVUH Pharmacy Department Document. Version 2. Updated by F. O'Regan. Approved by SIVUH Medication Safety Committee 08/2024, Drug & Therapeutics Committee 09/2024

### Appendix 1.

NURS0044: Policy for Medication Management for Nursing Staff in the SIVUH (Updated 10/2023), Page 32 & 33. Relevant for management of low magnesium at SIVUH.



\*HDU or equivalent setting with cardiac monitoring available







SIVUH Pharmacy Department Document. Version 2. Updated by F. O'Regan. Approved by SIVUH Medication Safety Committee 08/2024, Drug & Therapeutics Committee 09/2024

#### Management Pathway for the Patient receiving IV Magnesium for electrolyte disturbance.

Signs & Symptoms of hypomagnesaemia

Anorexia, Nausea

Confusion, Weakness, Ataxia, Paraesthesia, Tetany, Tremor, Muscle Fasciculation

Cardiac Arrhythmias, Digitalis toxicity may be exacerbated

With very low levels seizures, drowsiness and coma

#### Cautions & Side Effects of Magnesium supplementation

Adverse effects

Hypocalcaemia, phlebitis, hypermagnesaemia

Rapid IV administration may cause hypotension and flushing

Renal impairment increases the risk of hypermagnesaemia developing- consider dose alteration.

Caution should be taken with:

- patients with myasthenia gravis and hepatic failure
- patients with hyperkalaemia or hypocalcaemia
- parenteral magnesium in patients with heart block or myocardial damage

Magnesium toxicity can be treated with Calcium Chloride or Calcium Gluconate (please ensure same is available on the unit).

#### References:

Medinfo Galway (2020) Magnesium sulphate Intravenous for Adults.

The Royal Hospital for Women (2017) Magnesium Sulphate Intravenous Administration for Electrolyte Disturbance.

De Havilland A, Hariharan G and Puvvadi R. (2022) Is intravenous magnesium sulphate safe to be administered outside the critical care setting? Journal of Paediatrics and Child Health 58 924–92



